Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

patients with metastatic osteosarcoma treated in earlier Phase 2 studies. The biological effects and safety of L-MTP-PE are further supported by data from 7 other Phase 1 and 2 clinical studies performed under IND, in which an additional 197 patients received at least one dose of L-MTP-PE.

L-MTP-PE was granted orphan drug status in the United States in 2001. The NDA for L-MTP-PE was submitted to the U.S. Food and Drug Administration (FDA) in October 2006 and was accepted for review in December 2006.

The FDA's Oncologic Drugs Advisory Committee, or ODAC, met in May 2007 and voted 12 to 2 that the results of the Company's Phase 3 trial do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy. In July 2007, following a meeting with the FDA, the Company announced plans to collect, analyze and submit additional data for L-MTP-PE to the FDA, in an amendment to the NDA, by the first quarter of 2008. In August 2007 the FDA, considering ODAC's recommendation, issued a not approvable letter to the Company after completing the review of the NDA for L-MTP-PE. In this letter, the FDA requested data from additional clinical trials to demonstrate the benefit of L-MTP-PE, as well as information or clarification with respect to other sections of the NDA.

IDM Pharma also is seeking marketing approval from the European Medicines Agency (EMEA) for the use of L-MTP-PE, or MEPACT as it is known in Europe. L-MTP-PE was granted orphan drug status in Europe in 2004. The Marketing Authorization Application (MAA) for L-MTP-PE was submitted to the EMEA and accepted for review in November 2006. The EMEA application is currently under review and the Company continues to work closely with the regulatory body by providing as much additional data as possible and responding to ongoing inquiries from reviewers. The Company expects that the Committee for Human Medicina
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the ... and good people, all for a good cause. In its second year, the “Music ... more by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to ...
(Date:8/28/2015)... ... 28, 2015 , ... Healthpointe clinics throughout Southern California ... diving. The act of recreational diving exposes the body to extreme changes ... vital that all recreational and professional divers undergo regular comprehensive scuba physicals. Healthpointe’s ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan drug status ... any time soon, according to educational website Surviving Mesothelioma. Click here to read ... designation for mesothelioma last week from the FDA, will now head into Phase I ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... is pleased to welcome TJS Insurance Group as its newest Partner Firm. Founded ... guides them and keeps them focused on their goals. Within the past 10 ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known ... Clinic is now selling External Counterpulsation (EECP or ECP) machines with a full clinic ... has been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... savings comes an extra,hour of sleep, but how ... to the daily cup of coffee, early birds ... the Flower Promotion Organization at:, http://media.medialink.com/WebNR.aspx?story=34055 ) ... that study participants reported being happier and more ...
... Stryker Corporation,(NYSE: SYK ) announced today that it will participate in the ... 8:30 a.m. Mountain Standard Time Credit ... November 27, 2007 - 12:30 p.m. ... Care Conference New York, New York ...
... University Class Tests Benefits of Chewing Gum During Exam, ... can,be particularly stressful on college students as they struggle ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071101/AQTH193 ) "It,s common practice ... and pull all-nighters in preparation for exams," says Adrinda,Kelly, ...
... Centers, Inc.,("GNC" or the "Company"), announced today that it ... third quarter 2007 financial,results at 11 a.m. EST Thursday, ... the U.S., dial 1-888-895-5479, and,outside the U.S. dial 1-847-619-6250. ... webcast of the call will also be available,through the ...
... awards,Ashaway,s horse-assisted rehabilitative therapy with Premier Center Program ... ... Nov. 1 Turning Pointe,Therapeutic Riding has again been recognized ... the Handicapped Association (NARHA),the national standard bearer for therapeutic equine ...
... Kids,Indiana Action Fund launched an independent, direct ... supporting local elected officials who,have championed smoke-free ... - D) and Scott Keller (District 16 ... in passing Indianapolis, smoke-free,ordinance. The Indianapolis smoke-free ...
Cached Medicine News:Health News:Stryker to Present at Investor Conferences 2Health News:As Exams Loom, Students Find Hope in a 'Stick' 2Health News:As Exams Loom, Students Find Hope in a 'Stick' 3Health News:As Exams Loom, Students Find Hope in a 'Stick' 4Health News:Turning Pointe Therapeutic Riding Recognized for Excellence in Providing Equine-Assisted Therapies to People with Disabilities 2Health News:Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council 2Health News:Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council 3
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company plc ... the Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder ... "Our views of Mylan,s offer to Perrigo ... based on our Board,s careful reflection of the value ... the limited choices that Mylan has allowed its shareholders ...
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
(Date:8/28/2015)... FRANCISCO , August 28, 2015 ... expected to reach USD 49.12 billion by 2020, growing ... according to a new report by Grand View Research, ... estimated CAGR of 49.7% from 2014 to 2020. ... Growing aging population along with rising incidences of chronic ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development ... inihibtors have been validated to show survival benefits in cancer ... in combination with DNA damaging agents, and BMN 673 appears ...
... 2011 Virtual Radiologic (vRad), a technology-enabled national radiology ... the Teleradiology Services market segment by independent research and ... customer surveys and interviews conducted by KLAS and is ... in KLAS Awards: Software & Professional Services report. ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3Virtual Radiologic Ranked #1 for Teleradiology Services for Third Consecutive Year 2
10 mm angled blade with notches on sides and tip. Round knurled handle with polished finish....
1 mm wide by 33 mm long malleable blade. Flat serrated handle with polished finish....
Lasik spatula useful for protecting a previous flap for retreatment to lift and smooth the corneal flap....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 130o....
Medicine Products: